Accelerate to discover

Back to filter

Related topics

Quantitative characterization of metaphase cellular events using 3D imaging cellular events 

Yokogawa

Sep 20, 2018

In conventional monolayer cell culture systems, cell nuclei show dynamic and cyclic changes in theirshape and height....

A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy

Spectral Instruments Imaging

Sep 18, 2018

A polymeric conjugate, composed of a carboxymethyl dextran (CMD) as the backbone and ovalbumin (OVA) as a model foreign...

Adenovirus type B detection using the xxpress qPCR thermal cycler

BJS Biotechnologies

Sep 17, 2018

The ultrafast xxpress qPCR thermal cycler through performing standard dilution series and multiplex qPCR experiments is...

Contrast-enhanced ultrasound imaging

VisualSonics FujiFilm

Sep 5, 2018

Are you interested in photoacoustic imaging and would like to enhance your contrast imaging acquisitions? Just use...

Sep 21, 2018

BluePippin-DNA size selection for NGS with pulsed-field (100bp-50kb)

Sage Science

Sep 3, 2018

Highly sensitive detection of mutations in CHO cell recombinant DNA uses multi‐parallel single molecule real‐time DNA...

IncuCyte webinar: Live-cell analysis of cell subsets and heterogeneity

Sartorius

Sep 3, 2018

Discover the new IncuCyte S3 cell-by-cell analysis software module. The innovative module allow label free analysis to...

Diagnosis of Acute Cellular Rejection Using Probe-Based Confocal Laser Endomicroscopy in Lung

Mauna Kea Technologies

Sep 3, 2018

Mauna Kea Technologies announced the publication of a prospective multicenter study that demonstrates the potential of...

Sep 21, 2018

ACEA Biosciences introduces an exploratory xCELLigence RTCA S16 instrument

Acea Biosciences

Aug 30, 2018

The company has just introduced the xCELLigence RTCA S16, which is the ideal entry level model for exploratory studies...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey